參考文獻/References:
[1] Cai Q Q, Wang C, Cao X X,et al.Efficacy and safety of lowdose lenalidomide plus
dexamethasone in patients with relapsed or refractory POEMS syndrome[J].European
Journal of Haematology, 2015,95(4):325-330.
[2] Nozza A, Terenghi F, Gallia F, et al.Lenalidomide and dexamethasone in
patients with POEMS syndrome: results of a prospective, open-label trial[J].British
Journal of Haematology, 2017,179(5):748-755.
[3] Dispenzieri A.POEMS syndrome: 2017 Update on diagnosis, risk
stratification, and management[J].American journal of hematology, 2017,92(8):814-
829.
[4] Wang C, Huang X F, Cai Q Q, et al.Remarkable expression of vascular
endothelial growth factor in bone marrow plasma cells of patients with POEMS
syndrome[J].Leukemia Research, 2016,50:78-84.
[5] Misawa S, Sato Y, Katayama K, et al.Vascular endothelial growth factor as
a predictive marker for POEMS syndrome treatment response: retrospective cohort
study[J].BMJ Open, 2015,5(11):e009157.
[6] 季麗莉, 王欽, 張雪皎,等.血清血管內(nèi)皮生長因子在診斷 POEMS 綜合征中的作用(附
2例報告)[J].中國臨床神經(jīng)科學, 2016,24(3):288-293.
[7] Nasu S, Misawa S, Sekiguchi Y, et al.Different neurological and
physiological profiles in POEMS syndrome and chronic inflammatory demyelinating
polyneuropathy[J].J Neurol Neurosurg Psychiatry, 2012, 83(5):476-479.
[8] Piccione E A, Engelstad J, Dyck P J,et al.Nerve pathologic features
differentiate POEMS syndrome from CIDP[J].Acta Neuropathologica Communications,
2016,4(1):116.
[9] Li J, Zhou D B, Huang Z, et al.Clinical characteristics and long-term
outcome of patients with POEMS syndrome in China[J].Annals of Hematology, 2011,90
(7):819-826.
[10] 周道斌, 李劍.POEMS 綜合征的診斷和治療[J].中國腫瘤臨床, 2014,41(13):831-
835.